ArticleFrontiers in oncology2025

Different therapeutic responses to osimertinib as first-line treatment for cavitated and non-cavitated squamous cell lung cancer with rare EGFR exon 19 deletion: two case reports and a literature review.

Jing Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.